<DOC>
	<DOC>NCT01065246</DOC>
	<brief_summary>This phase II single arm, open-label study investigate the safety of a second cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study.</brief_summary>
	<brief_title>Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites</brief_title>
	<detailed_description>Up to 30 evaluable patients from the CASIMAS study will be enrolled. Catumaxomab will be infused intraperitoneally with 3hour constant-rate infusions 4 times within 11 days with ascending dosages (10 - 20 - 50 - 150 Âµg).</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Antibodies, Bispecific</mesh_term>
	<criteria>patients who have completed 4 infusions of catumaxomab in the CASIMAS study age &gt;= 18 years Karnofsky index &gt;= 60 % patients with malignant ascites requiring their first therapeutic ascites paracentesis after at least 60days following last catumaxomab infusion in the CASIMAS study Patients where standard therapy is either not available or no longer feasible acute or chronic infection concomitant treatment with investigational products other than catumaxomab, cancer, chemo or radiotherapy previous treatment with entirely murine monoclonal antibodies other than catumaxomab liver metastases with volume &gt;70 % of liver metastasized tissue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>malignant ascites</keyword>
	<keyword>second cycle</keyword>
	<keyword>trifunctional</keyword>
</DOC>